A股異動丨豬肉概念股拉昇 巨星農牧一度漲6% 新五豐漲超4%
A豬肉概念股逆勢拉昇,其中,巨星農牧一度漲至6%,新五豐漲超4%,神農集團、華統股份、溫氏股份、金新農、唐人神、牧原股份跟漲。消息上,三大上市豬企牧原股份、新希望、溫氏股份近日發佈2025年2月生豬銷售情況簡報。從銷量看,牧原股份、溫氏股份1-2月份生豬銷量同比均增長,新希望同比下降。2月份,溫氏股份和新希望的生豬銷量環比均下降,溫氏股份同比增長,新希望同比下降。神農集團2月生豬銷售量爲28.14萬頭,同比增長114.97%。此外,據知情人士透露,牧原股份正在考慮在香港進行第二次上市,這可能有助於其籌集至少10億美元的資金。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.